The first clinical trial studying the effects of semaglutide, commonly known as Ozempic and Wegovy, reported a 40% decrease in daily alcohol consumption among participants with alcohol use disorder. This 9-week study involved 48 individuals, highlighting the drug's promising benefits beyond weight loss and diabetes management, such as its potential role in curbing alcohol cravings. Given rising alcohol-related deaths in the UK and Ireland, these findings could open new avenues for treatment in addressing alcohol dependency issues.
Researchers observed a 40% reduction in weekly alcohol consumption among participants receiving semaglutide, shedding light on the drug's potential role in treating alcohol use disorder.
The study reveals that semaglutide not only aids in weight loss and diabetes management, but may also offer significant benefits for individuals struggling with alcohol dependencies.
Collection
[
|
...
]